IMPACT THERAP-B (07630) has announced that the over-allotment option detailed in the prospectus has been fully exercised by the overall coordinators on Friday, June 5, 2026. This action, taken on behalf of themselves and the international underwriters, involves a total of 6.2964 million H shares. This quantity represents approximately 15% of the total number of shares initially available for subscription under the global offering prior to any exercise of the over-allotment option.

The H shares to be issued as a result of this exercise, referred to as the over-allotment shares, will be issued and allotted by the company at a price of HK$20.10 per H share.

The proceeds from the issuance of these over-allotment shares will be used to expedite the delivery of a portion of H shares to placees who have agreed to a delayed delivery of the H shares they subscribed for under the global offering.